Lekha Mikkilineni
@LMikkMD
Followers
464
Following
944
Media
1
Statuses
94
Assistant Professor in the BMT Division at Stanford University School of Medicine . I focus on multiple myeloma and CAR T-cell therapy.
Palo Alto, CA
Joined July 2018
We studied stem cell mobilization in the CD38-mAb era. š§¬ In NDMM pts undergoing ASCT, CD38-mAb induction led to:.ā¢ ā yields (ā9.4%).ā¢ ā plerixafor & apheresis.ā¢ +$23K mobilization costs.Longer washout improved yields. š
pubmed.ncbi.nlm.nih.gov
CD38 mAb-containing induction regimens were associated with inferior stem cell mobilization yields and higher resource utilization. Extended washout periods modestly improved yield, highlighting a...
1
3
14
RT @thisisJamesD: CAR T-cell therapy for the beast that is plasma cell leukemia #PCL. š led by Doug Sborov and team at @huntsmancancer httā¦.
0
21
0
The most fun image & video creation tool in the world is here. Try it for free in the Grok App.
0
162
2K
RT @RahulBanerjeeMD: 1/ Our call to action is out in @BloodAdvances!. Title speaks for itself. Given concerningly high infection risk withā¦.
0
37
0
RT @ZainabShd: Sharing our work to help our CAR T-cell therapy pts, vaccine response varies by antigen:.ā
100%: Polio & Tetanus.š” ~50%: Hepā¦.
nature.com
Blood Cancer Journal - Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
0
3
0
RT @RahulBanerjeeMD: 1/ Now in @BloodCancerJnl: Algorithm for IEC-associated enterocolitis following CAR-T in myeloma. Companion #MMsm pieā¦.
0
6
0
RT @RahulBanerjeeMD: Great @BloodCancerJnl RW data from US #MMsm consortium, led by @DimaDanai @leshune et al!. BCMA bsAbs can work in BCMAā¦.
0
15
0
Extending access for life-saving CAR-T therapies!
fda.gov
The REMS for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been eliminated because the FDA has determined that a REMS is no longer...
2
6
33
RT @AnmolGoyalMD: Honored be chosen for a YIP scholarship to attend #SOHO2025! Grateful for the support, and excited to learn from and meetā¦.
0
2
0
RT @JoshuaRichterMD: ā¦@GKaurMDā© is an absolute superstar ! #mmsm ā¦@TischCancerā© ā¦@MountSinaiNYCā©
0
6
0
RT @TomBmt133: Dr Kaur - wonderful job presenting 117 RRMM pats treated with Anito-cel => ORR 97%, no late neurotoxicity to date - interestā¦.
0
10
0
RT @VincentRK: On being a good doctor .Part II (after being on the other side as a patient advocate). - Understand the patient and the clinā¦.
0
22
0
RT @AdamRodmanMD: Valuable perspective on the regulatory structures necessary to make automated prescribing safe -- but perhaps more importā¦.
0
5
0
RT @UrviShahMD: Our study on dietary risk factors for MGUS made the list of the 2024 @BloodAdvances most read articles @JanineMJoseph . httā¦.
ashpublications.org
Consumption of whole-grain bread, oats, and rice (PĀ < .05), and fruits and vegetables (PĀ =.02) were associated with reduced risk of MGUS.Intake of suga
0
10
0
RT @SurbhiSidanaMD: #ASH24 #bmtsm Dr Melody Smith presented Stanford trial combining academic allogeneic transplant and donor CAR-T in ALL.ā¦.
0
1
0
RT @MSKCancerCenter: Learn more about @UrviShahMD's new study that reveals a #fiber diet may delay #multiplemyeloma. #ASH24 @ASH_hematologā¦.
0
8
0
RT @MM_Hub: CONGRESS | #ASH24 | @RahulBanerjeeMD @UWMedicine @fredhutch discusses the rationale for moving toward urine-free response criteā¦.
0
8
0
RT @SneghaAnanth: Congratulations Dr. Bharadwaj and grateful to Dr. Weng for leading this fellowship. One of the best experiences Iāve hadā¦.
0
2
0
RT @RahulBanerjeeMD: 1/ šØ Now in @BloodCancerJnl - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-Tā¦.
0
44
0